BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Trials

Antengene Receives CDE Endorsement For Pivotal Phase III Study Of CLDN18.2 ADC In Gastric Cancer

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, d...

May 29, 2026 | News

Ribo Submits Phase 2 CTA To EMA For siRNA Therapy Targeting Coronary Artery Disease

Suzhou Ribo Life Science (stock code 06938.HK) and Ribocure Pharmaceuticals (together "Ribo") announce the submission of Phase 2 Clinical Trial Application...

May 29, 2026 | News

CGBIO Expands Global NOVOSIS Partnership With DePuy Synthes Into North America And Australia

DePuy Synthes secures exclusive commercialization rights in North America and Australia; the two companies to jointly advance global clinical development...

May 28, 2026 | News

Kazia Therapeutics Expands Paxalisib TNBC Trial Following Encouraging Early Safety Data

Planned Enrollment to Increase from 12 to 36 Patients Following Continued Encouraging Safety and Tolerability Data Kazia Therapeutics Limited (NASDAQ...

May 28, 2026 | News

Pierre Fabre Laboratories Receives CHMP Positive Opinion For BRAFTOVI Combination In First Line BRAF Mutant Metastatic Colorectal Cancer

This positive CHMP opinion is based on results from the Phase 3 BREAKWATER trial, which showed that encorafenib in combination w...

May 27, 2026 | News

AGC Biologics Selected By Teikoku Seiyaku Co., Ltd. To Advance Microbial Manufacturing For KTP 001 Disc Herniation Therapy

AGC Biologics, your friendly CDMO expert, was selected by Teikoku Seiyaku Co., Ltd., a leader in transdermal drug delivery, to provide microbial contract d...

May 27, 2026 | News

Caliway Advances Global Phase 3 Programme For CBL 514 Following U.S. FDA IND Clearance

Asia-Pacific Phase 2 Study CBL-0206 Also Approved by Australia HREC and Taiwan TFDA, Accelerating Global Dual-Track Strategy ...

May 26, 2026 | News

Scribe Therapeutics Gains Australian Clearance To Begin First Human Trial Of STX 1150 For Hypercholesterolemia

Scribe Therapeutics, Inc. (Scribe), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to exte...

May 26, 2026 | News

Ingenia Therapeutics Secures KRX Approval For IPO Amid Advancing TIE2 Targeted Pipeline

Ingenia Therapeutics, a clinical-stage biotechnology company pioneering next-generation vascular-targeted therapies, announced that the company has receive...

May 26, 2026 | News

Hyundai Bioscience Positions XAFTY As Potential Ebola And Hantavirus Treatment Following Strong IC50 Findings

Ebola IC50 (0.125μM)—Strong inhibition at less than half the concentration of the clinically-tested COVID-19 (0.28μM). Clinical safety confi...

May 22, 2026 | News

Kivo Launches Headless GxP Architecture To Power AI Native Drug Development Workflows

New open architecture connects AI agents, regulated workflows, and human-authenticated action to Kivo’s GxP-compliant platform. Kivo, the unified do...

May 21, 2026 | News

HaemaLogiX Opens Phase 1 KOALA Trial Of KMCAR T Cell Therapy For Relapsed Multiple Myeloma

Phase 1 KOALA clinical trial evaluating KMCAR™ T-cell therapy in relapsed/refractory kappa-restricted multiple myeloma now open for patient enrolme...

May 21, 2026 | News

Accro Bioscience Secures $50 Million Series C Financing To Advance Immune Disease Pipeline

Financing led by OrbiMed with participation from TCGX, LAV, Cenova Capital and existing investors SCGC and Oriza Proceeds will advance multi-asset ...

May 20, 2026 | News

Thermo Fisher Scientific Expands PPD Laboratory Services Network With New Bioanalytical Facility In Sweden

The state-of-the-art facility enhances support for complex modalities across all phases of drug development Key facts Thermo Fisher opens new bioa...

May 19, 2026 | News

Stay Connected